PITTSBURGH, June 3 /PRNewswire/ -- A study demonstrating the cost savings realized through the use of the ChemoFx® Drug Response Marker for assisting selection of treatment in recurrent ovarian cancer was published recently in the American Journal of Obstetrics and Gynecology (AJOG).
This economic analysis of recurrent ovarian cancer patients studied the direct costs of chemotherapy for three groups; empiric, assay-assisted, and assay-adherent. This study demonstrated that ChemoFx®-assisted chemotherapy may result in substantially reduced costs compared with empiric therapy.
The publication, titled, "Impact of a Chemoresponse Assay on Treatment Costs for Recurrent Ovarian Cancer," evaluated the net cost savings associated with the use of the ChemoFx® drug response marker to aid therapeutic decisions in the setting of recurrent ovarian cancer, and reveals a possible cost savings of $15,600 to $24,800.
"In this tough economic time it is exciting to see cost savings resulting from the personalized information provided by ChemoFx® for cancer patients, physicians and the health care system," said Sean McDonald, CEO of Precision Therapeutics.
About Precision Therapeutics
Precision Therapeutics, a life sciences company and leader in the development of innovative technology, delivers personalized diagnostics to physicians with the goal of supporting and optimizing difficult treatment decisions for patients with cancer.
Precision's ChemoFx®, a proprietary drug response marker, measures an individual patients' tumor response to a range of therapeutic alternatives under consideration by a physicia